Spun-out from IIT-Bombay in 2018, ImmunoACT is India's pioneer of Gene-modified Cell Therapies, having launched the country's first CAR-T cell therapy for treatment of certain B-cell malignancies. With a rapidly expanding pipeline beginning, our mission is to provide affordable access to novel CAR-T cell therapies.
| Website | http://immunoact.com |
| Employees | 193 (169 on RocketReach) |
| Founded | 2018 |
| Address | ImmunoACT, 1st Floor, R-977, T.T.C. Industrial Area, MIDC Rabale, Navi Mumbai, Maharashtra 400701, IN |
| Phone | +1 310-953-4444 |
| Industry | Biotechnology Research |
| Keywords | Cell Therapy, Gene Therapy, Cellular Therapy, Cancer Treatment, Oncology, Immunotherapy, Blood Cancer Treatment, Biotechnology, Pharmaceutical, Hematology, Drug Development, Regenerative Medicine, Advanced Therapies, Innovative Therapies, Precision Medicine, Personalized Medicine, Clinical Trials, Therapeutic Solutions, Biologics, Life Sciences |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck AH, Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences +42 more (view full list) |
Looking for a particular ImmunoACT employee's phone or email?
Atharva Karulkar is the Co-Founder of ImmunoACT.
169 people are employed at ImmunoACT.
ImmunoACT is based in Navi Mumbai, Maharashtra.